GRAIL projects strong growth momentum ahead. The company signaled 22 to 32 percent revenue growth for 2026, driven by expanding Galleri test volumes and successful Epic Aura system integrations. During its Q1 earnings call, GRAIL highlighted progress on its FDA PMA review process, a critical milestone for broader market adoption. The Epic Aura rollout represents a significant operational expansion that could accelerate customer adoption across healthcare systems. With growing clinical validation and increasing test utilization, GRAIL appears positioned to capture greater market share in the liquid biopsy sector. Investors are watching the FDA approval timeline closely as a potential catalyst for accelerated growth and profitability improvements in the coming quarters.
Post from MarketNews_en
Log in to interact with content.